FDA Grants Orphan Drug Designation to TP-1287 for Ewing Sarc

The FDA has granted an orphan drug designation to TP-1287, an investigational oral CDK9 inhibitor, for the treatment of patients with Ewing sarcoma.

Related Keywords

Sumitomo Dainippon Pharma , Jatinj Shah , Patricias Andrews , Sumitomo Pharma Oncology Inc , , Sumitomo Pharma Oncology , Sumitomo Pharma , Pharma Oncology , Dainippon Pharma Oncology , Dainippon Pharma , Tp 1287 , Fda , Ewing Sarcoma , Cdk9 Inhibitor , Nct03604783 ,